All News
ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD trials. Formats include mean (±SD), mean change, and categorical thresholds for ASDAS, ASAS-HI, and extra-musculoskeletal manifestations. 85% of ASAS members https://t.co/VQwPaTRIOl
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Poster evaluating representation in trials of AAV and GCA
Results mirror those observed in other fields; need to keep advocating for trials in all populations!
#ACR25 @RheumNow Abstr#0720 https://t.co/gDj5IQMJOc
Mike Putman EBRheum ( View Tweet)
In a novel Geri-Rheum clinic, cognitive screening revealed 35% impairment among adults >55 yrs.
Common deficits: visuospatial, attention & recall.
Early geriatric screening = earlier intervention.
A model for age-friendly rheum care in action.
@RheumNow #ACR25 Abstract #0226 https://t.co/lIAcrZvL4H
Jiha Lee JihaRheum ( View Tweet)
#ACR25 Abstr#775 Previous study showed plasma tRNA-derived RNA (tDR-1), produced by bacteria from the phylum Proteobacteria, was assoc. with lower RA activity.
In 60 At-Risk CCP3+ people, Plasma tDR-1 improved prediction of RA. Need validation & adoption in practice @RheumNow https://t.co/XBmtohBEHc
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#0191 We found that in a large South London RA cohort, use of advanced therapy in moderate disease (DAS28 3.2-5.1) generally followed NICE guidance. Gaps often reflected telehealth limiting DAS assessment and patient hesitancy. Self-assessment tools may help. @RheumNow #ACR25 https://t.co/UMGtkfABHn
Mrinalini Dey DrMiniDey ( View Tweet)
Real-world T2T strategy from MONITOR-PsA cohort:
🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' response & 37% (54/146) achieved a 'good' response
This was close to the T2T outcomes of the TICOPA trial
Adapt a T2T approach in PsA tx
#ACR25 @RheumNow Abs0572 https://t.co/FPiFIiO8Oe
Links:
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Post-hoc PEXIVAS study, estimating risk of relapse from baseline variables
Lotsa fancy stats, mostly corroborated known risk factors, but model predicted relapse reasonably well!
Probably useful for approach to monitoring... mayyybe treatment?
#ACR25 @RheumNow #Abstr0722 https://t.co/XI9y8KgDNR
Links:
Mike Putman EBRheum ( View Tweet)
Tracking RA disease activity got a measurable boost in the VA: a 3-month multimodal rollout (feedback, EHR tools, just-in-time lists) raised DAM documentation up to 10%. Small structural changes, big data gains.
@RheumNow #ACR25 Abstract#0221
Jiha Lee JihaRheum ( View Tweet)
Ribeiro et al. Case series of combination bDMARD/tsDMARD in PsA from Toronto. 24 patients, median just over a year follow-up. Appear effective, especially for objective skin and joint measures. No major safety concerns but short follow-up to date. @RheumNow #ACR25 Abstr#565 https://t.co/Zk3odT2EX2
Richard Conway RichardPAConway ( View Tweet)
Why do some clinics excel at RA disease activity tracking while others struggle? In the VA, success came down to structure: RA-specific clinics, templates, and staff. Barriers? Time, missing labs, and workflow gaps.
@RheumNow #ACR25 Abstract#0222
Jiha Lee JihaRheum ( View Tweet)
Abstract 0196: Too many referrals, too few slots? A hybrid RN + MD referral cut wait times for patients with SLE by 26%
Median time to appointment 69 days --> 51 days
Next steps: streamline high-risk triage, reduce manual chart review
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Abstract #0189: Rheumatologists are early adopters and high utilizers of #AI scribes.
📊 Adoption: 41%
🧑💻 Retention: 100%
💬 High utilizers (> 70% visits): 83%. The highest among IM subspecialties
🕒 AI scribes reduced EHR time across all measures.
@RheumNow #ACR25 https://t.co/TBurWUKhMl
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello!
(and Ask Cush Anything - scan the QR code, and maybe end up on the podcast!) https://t.co/0u0boHIIR3
David Liew drdavidliew ( View Tweet)
Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ilKWG8CQbe
Dr M Nazibur Rahman, MD (Rheumatology) NaziburM ( View Tweet)
#Pros and #cons of #AI
Need to know both
Need to assess AI #quality and #accuracy
‘Assume AI WILL be used’
JHausmann
By trainees, patients and medical personnel
Train #faculty re #AI
#ACR25 @RheumNow @ACRheum
#26S17 https://t.co/CvPDQPbueW
Janet Pope Janetbirdope ( View Tweet)
#AI for medical use is fast moving
governance is Impt
Protect Privacy
Facilitate trainees to LEARN
Involve #IT, ethicists, users
‘We will enter a world where all we do medically is recorded’ J Hausmann said
#ACR25 @RheumNow @ACRheum
#26S17 https://t.co/zWjy4u99Yo
Janet Pope Janetbirdope ( View Tweet)
#Medical #learners more optimistic re #AI than gen pop’n!
Tips
stress privacy
- pt info in AI goes to private company
All trainees will use #AI
Set boundaries - change eval where can’t use AI
only AI listening notes
👇
#cognitive #deskilling
#ACR25 @RheumNow @ACRheum
26S17 https://t.co/UzajaimOcG
Janet Pope Janetbirdope ( View Tweet)
Don’t fight #AI
#RCTs - #AI better at soft
Skills alone
Vs
#Medical input and AI as we tend to
Disbelieve the model & mess it up!
#LLM can accurately take a #history
Bottom line EMBRACE AI ?check it too
#ACR25 @RheumNow @ACRheum
#artificial #intelligence and #medicine
26217 https://t.co/22MYD4QqzH
Links:
Janet Pope Janetbirdope ( View Tweet)
Rheum guidelines balance data & context.
Beyond evidence, factors like cost, equity & feasibility shape recs.
GRADE-ADOLOPMENT = global tool to adopt, adapt, or design local guidance for more rapid integration and with less $$$
@RheumNow #ACR25 #GlobalRheumSummitt https://t.co/Sfsqxsqpt4
Jiha Lee JihaRheum ( View Tweet)
